fbpx

molecules of the month

AZD4573

short engagement, selective CDK9 kinase inh.

IV treatment in Ph. I for RR-heme cancers

shortened t1/2 from prior preclin. candidate

J. Med. Chem., Dec. 11, 2020

AstraZeneca, Cambridge, UK / Boston, MA

Structure of AZD4573, a potent and selective inhibitor of CDK9
1 min read

AstraZeneca selective CDK9 kinase inhibitor


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: